- Home
- TRLV vs GHRS Comparison
TRLV vs GHRS Comparison
Compare TRLV & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TRLV | GHRS |
|---|---|---|
| Founded | N/A | 2018 |
| Country | | Ireland |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.0B |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | TRLV | GHRS |
|---|---|---|
| Price | $12.31 | $23.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $41.38 |
| AVG Volume (30 Days) | ★ 1.9M | 150.4K |
| Earning Date | N/A | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 26.58 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,181,180,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.82 | $12.04 |
| 52 Week High | $12.93 | $31.44 |
Technical Indicators
Market Signals| Indicator | TRLV | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 62.76 | 26.61 |
| Support Level | $10.71 | $19.75 |
| Resistance Level | $12.76 | $25.30 |
| Average True Range (ATR) | 0.77 | 1.29 |
| MACD | -0.01 | -0.50 |
| Stochastic Oscillator | 75.68 | 5.58 |
Price Performance
Historical ComparisonAbout TRLV Trulieve Cannabis Corp. Subordinate Voting Shares
Trulieve Cannabis Corp is a vertically integrated cannabis company that grows, produces, and sells cannabis products. It has licenses to operate in Arizona, Colorado, Connecticut, Florida, Georgia, Maryland, Ohio, Pennsylvania, and West Virginia, where it sells medical cannabis products. In addition, the company sells cannabis products for adult use in Arizona, Colorado, Connecticut, Maryland, and Ohio. The firm's operations are substantially located in Florida and, to a lesser extent, in Arizona and Pennsylvania.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.